AC Immune (NASDAQ:ACIU) Upgraded at StockNews.com

StockNews.com upgraded shares of AC Immune (NASDAQ:ACIU) from a hold rating to a buy rating in a research report report published on Tuesday morning.

Separately, HC Wainwright lowered their target price on shares of AC Immune from $16.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, May 1st.

AC Immune Stock Performance

Shares of NASDAQ:ACIU opened at $1.57 on Tuesday. AC Immune has a 52 week low of $1.43 and a 52 week high of $4.98. The company has a market capitalization of $157.64 million, a PE ratio of -3.41 and a beta of 1.62. The company has a 50 day moving average price of $1.77 and a two-hundred day moving average price of $2.48.

AC Immune (NASDAQ:ACIU) last issued its earnings results on Wednesday, April 30th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.01. The firm had revenue of $1.12 million during the quarter, compared to the consensus estimate of $1.99 million. On average, sell-side analysts forecast that AC Immune will post -0.62 earnings per share for the current year.

Institutional Investors Weigh In On AC Immune

Several large investors have recently made changes to their positions in ACIU. Northern Trust Corp bought a new stake in shares of AC Immune during the fourth quarter worth $1,088,000. Renaissance Technologies LLC increased its position in shares of AC Immune by 14.6% during the fourth quarter. Renaissance Technologies LLC now owns 740,198 shares of the company’s stock worth $1,999,000 after acquiring an additional 94,191 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of AC Immune by 130.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 131,410 shares of the company’s stock worth $355,000 after acquiring an additional 74,358 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of AC Immune during the fourth quarter worth $118,000. Finally, Banque Cantonale Vaudoise bought a new position in AC Immune in the first quarter valued at $50,000. Institutional investors own 51.36% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.